![Thomas Mehrling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Mehrling
Vorstandsvorsitzender bei
HELIX BIOPHARMA CORP.
Vermögen: 50 290 $ am 31.07.2026
Profil
Thomas J.
Mehrling is the founder of Laevoroc Oncology AG, founded in 2019, where Dr. Mehrling holds the title of Chief Executive Officer.
Dr. Mehrling was the founder of Mundipharma EDO GmbH, founded in 2013, where Dr. Mehrling held the title of Chief Executive Officer.
Dr. Mehrling is also the founder of Laevoroc Immunology AG..
Dr. Mehrling is Chief Executive Officer at Release Therapeutics SA since 2024.
Dr. Mehrling is Chief Executive Officer at Helix BioPharma Corp.
starting in 2025.
Dr. Mehrling is Chairman & Chief Executive Officer at Laevoroc Chemotherapy AG.
Dr. Mehrling was Managing Director-European Oncology at Mundipharma International Ltd. from 2003 to 2013.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2026 | 47’000 ( 0.06% ) | 50 290 $ | 31.07.2026 |
Aktive Positionen von Thomas Mehrling
| Unternehmen | Position | Beginn |
|---|---|---|
| HELIX BIOPHARMA CORP. | Vorstandsvorsitzender | 10.04.2025 |
Laevoroc Oncology AG
 Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Vorstandsvorsitzender | 01.02.2019 |
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Vorstandsvorsitzender | 27.06.2024 |
Ehemalige bekannte Positionen von Thomas Mehrling
| Unternehmen | Position | Ende |
|---|---|---|
Mundipharma EDO GmbH
 Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Vorstandsvorsitzender | 01.07.2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Corporate Officer/Principal | 01.01.2013 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
23
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Helix BioPharma Corp.
 Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Mundipharma EDO GmbH
Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Commercial Services |
Laevoroc Oncology AG
Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Health Technology |
